Yoshikuni Mizuno

Q: What Schools Are Affiliated With Yoshikuni Mizuno

Yoshikuni Mizuno is affiliated with the following schools: Kitasato University, Juntendo University

Yoshikuni Mizuno's AcademicInfluence.com Rankings

Yoshikuni Mizuno

Biology

#8210

World Rank

#11251

Historical Rank

Neuroscience

#1121

World Rank

#1163

Historical Rank

biology Degrees

Download Badge

Biology

Yoshikuni Mizuno's Degrees

PhD Medicine University of Tokyo

Why Is Yoshikuni Mizuno Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Yoshikuni Mizuno's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism (1998) (4916)
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase (2000) (2014)
Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease (2001) (1064)
An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin (2001) (1036)
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. (1996) (960)
Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force (2007) (918)
Protein-bound acrolein: potential markers for oxidative stress. (1998) (595)
Mitochondrial genome variation in eastern Asia and the peopling of Japan. (2004) (525)
Histochemical detection of apoptosis in Parkinson's disease (1996) (472)
Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. (1996) (424)
Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. (1997) (384)
Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease (1999) (368)
Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue (2012) (328)
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. (2002) (325)
A possible role for humoral immunity in the pathogenesis of Parkinson's disease. (2005) (299)
Methylglyoxal Modification of Protein (1999) (295)
Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the Parkin gene in affected individuals (1998) (293)
Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in parkinson's disease (1991) (279)
Immunohistochemical and subcellular localization of parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients (1999) (269)
Clinical heterogeneity of α‐synuclein gene duplication in Parkinson's disease (2006) (265)
CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study (2015) (265)
Edaravone Reduces Early Accumulation of Oxidative Products and Sequential Inflammatory Responses After Transient Focal Ischemia in Mice Brain (2005) (260)
Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin‐like domain (2003) (258)
Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. (2005) (246)
Overexpression of α‐synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α‐synuclein and activation of caspase‐9: resemblance to pathogenetic changes in Parkinson's disease (2004) (236)
Novel PINK1 mutations in early‐onset parkinsonism (2004) (228)
p53 protein, interferon-γ, and NF-κB levels are elevated in the parkinsonian brain (2007) (197)
Neuroprotective Effect of Recombinant Human Granulocyte Colony-Stimulating Factor in Transient Focal Ischemia of Mice (2006) (186)
Diverse Effects of Pathogenic Mutations of Parkin That Catalyze Multiple Monoubiquitylation in Vitro* (2006) (185)
Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. (2006) (183)
Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease (2013) (179)
An immunohistochemical study on α‐ketoglutarate dehydrogenase complex in Parkinson's disease (1994) (175)
Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. (1995) (172)
Effect of Wild-type or Mutant Parkin on Oxidative Damage, Nitric Oxide, Antioxidant Defenses, and the Proteasome* (2002) (172)
Clinical efficacy of istradefylline (KW‐6002) in Parkinson's disease: A randomized, controlled study (2010) (166)
Milestones in PD genetics (2011) (163)
A reassessment of risks and benefits of dopamine agonists in Parkinson's disease (2009) (163)
A Combinatorial Code for the Interaction of α-Synuclein with Membranes* (2005) (162)
Point Mutations (Thr240Arg and Ala311Stop) in theParkinGene (1998) (161)
Increased 8‐oxo‐dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease (1999) (160)
An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease (2001) (151)
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial (2013) (149)
Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism (2005) (147)
Leucine-rich repeat kinase 2 associates with lipid rafts. (2007) (147)
Apoptosis is induced by 1-methyl-4-phenylpyridinium ion (MPP+) in ventral mesencephalic-striatal co-culture in rat (1994) (146)
[Clinical subtypes of Parkinson's disease]. (1993) (139)
Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease (1990) (133)
Pathogenetic mechanisms of parkin in Parkinson's disease (2004) (133)
Leucine-Rich Repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population (2007) (132)
Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations (2006) (132)
Possibility for neurogenesis in substantia nigra of parkinsonian brain (2005) (131)
Parkin is associated with cellular vesicles (2001) (131)
Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys (1994) (130)
Expanding the clinical phenotype of SNCA duplication carriers (2009) (127)
Caspase-11 Mediates Inflammatory Dopaminergic Cell Death in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson's Disease (2004) (122)
Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries (2006) (122)
Diagnostic Accuracy of 123I-Meta-Iodobenzylguanidine Myocardial Scintigraphy in Dementia with Lewy Bodies: A Multicenter Study (2015) (121)
Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson’s disease and related neurodegenerative disorders (2005) (120)
Neurotoxic Effects of Lipopolysaccharide on Nigral Dopaminergic Neurons Are Mediated by Microglial Activation, Interleukin-1β, and Expression of Caspase-11 in Mice* (2004) (119)
Ubiquitin, proteasome and parkin. (2004) (118)
Multiplex families with multiple system atrophy. (2007) (116)
p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. (2007) (116)
Parkin and Parkinson's disease (2001) (115)
Parkin attenuates manganese‐induced dopaminergic cell death (2004) (115)
Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease (2005) (113)
The fate of neural progenitor cells expressing astrocytic and radial glial markers in the postnatal rat dentate gyrus (2005) (113)
Cilostazol Protects Against Brain White Matter Damage and Cognitive Impairment in a Rat Model of Chronic Cerebral Hypoperfusion (2006) (112)
bcl-2 Protein is increased in the brain from parkinsonian patients (1996) (112)
Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. (2005) (111)
14‐3‐3η is a novel regulator of parkin ubiquitin ligase (2006) (111)
A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease (2015) (110)
Binding of laminin-1 to monosialoganglioside GM1 in lipid rafts is crucial for neurite outgrowth (2009) (110)
Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's disease-associated UCH-L1 I93M mutant (2007) (104)
The soluble form of Fas molecule is elevated in parkinsonian brain tissues (1996) (102)
Siah-1 Facilitates Ubiquitination and Degradation of Synphilin-1* (2003) (102)
Polymorphism of the Lipoprotein Lipase Gene and Risk of Atherothrombotic Cerebral Infarction in the Japanese (2001) (101)
Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity by 1-methyl-4-phenylpyridinium ion. (1987) (100)
A combinatorial code for the interaction of alpha-synuclein with membranes. (2005) (98)
Neurogenesis After Transient Global Ischemia in the Adult Hippocampus Visualized by Improved Retroviral Vector (2004) (96)
Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. (1987) (95)
Polymorphism in the parkin gene in sporadic Parkinson's disease (1999) (94)
Malignant syndrome in Parkinson's disease: concept and review of the literature. (2003) (94)
Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro (2006) (94)
A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. (2003) (92)
Pergolide in the treatment of Parkinson's disease (1984) (90)
Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease (2006) (89)
Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease (2010) (89)
Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain in vivo (1988) (88)
GTP‐cyclohydrolase I gene mutations in hereditary progressive and dopa‐responsive dystonia (1996) (88)
Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2 (2005) (88)
Relationship of phosphorylated α-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies (2008) (87)
Autosomal recessive parkinsonism linked to parkin gene in a Tunisian family. Clinical, genetic and pathological study. (2003) (85)
Familial Parkinson's disease. Alpha-synuclein and parkin. (2001) (83)
Progress in the pathogenesis and genetics of Parkinson's disease (2008) (82)
Parkin stabilizes PINK1 through direct interaction. (2009) (82)
Mitochondrial dysfunction in parkinson's disease (1998) (81)
Neurotrophic and neuroprotective effects of neuron-specific enolase on cultured neurons from embryonic rat brain (1995) (81)
Down-regulation of α-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson’s disease rat model ☆ (2006) (80)
Extended-release pramipexole in early Parkinson disease (2011) (80)
Inhibition of ATP synthesis by 1-methyl-4-phenylpyridinium ion (MPP+) in isolated mitochondria from mouse brains (1987) (79)
Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification (2000) (79)
Mutation analysis of the PINK1 gene in 391 patients with Parkinson disease. (2008) (78)
Neurogenesis in olfactory bulb identified by retroviral labeling in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated adult mice (2004) (78)
Is Parkinson's disease a mitochondrial disorder? (1992) (77)
Effect of Dopamine, Dimethoxyphenylethylamine, Papaverine, and Related Compounds on Mitochondrial Respiration and Complex I Activity (1996) (77)
Parkin is linked to the ubiquitin pathway (2001) (74)
Reciprocal Ia inhibition in patients with asymmetric spinal spasticity (2002) (74)
Generalized Convulsions After Consuming a Large Amount of Gingko Nuts (2001) (73)
A novel L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology (2003) (73)
Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease (2003) (72)
Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: Implications of autophagy promotion (2012) (72)
Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP+) against mitochondria of mouse brain (1988) (71)
PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations (2004) (71)
Parkin Cleaves Intracellular α-Synuclein Inclusions via the Activation of Calpain* (2003) (71)
Feasibility of ex vivo gene therapy for neurological disorders using the new retroviral vector GCDNsap packaged in the vesicular stomatitis virus G protein (2002) (70)
Neurochemical and Neurogenetic Correlates of Parkinson's Disease (1998) (69)
Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release (2014) (68)
Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene (2000) (68)
Point mutations (Thr240Arg and Gln311Stop) [correction of Thr240Arg and Ala311Stop] in the Parkin gene. (1998) (64)
Pro‐apoptotic protein glyceraldehyde‐3‐phosphate dehydrogenase promotes the formation of Lewy body‐like inclusions (2005) (63)
The neuromythology of Parkinson's Disease. (2004) (62)
Functional effects of NAD(P)H oxidase p22(phox) C242T mutation in human leukocytes and association with thrombotic cerebral infarction. (2004) (62)
Long-term effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine content in young and mature mice (1987) (61)
Clinical trial of piracetam in patients with myoclonus: Nationwide multiinstitution study in Japan (1996) (61)
Changes in superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activities and thiobarbituric acid-reactive products levels in early stages of development in dystrophic chickens (1984) (60)
Parkin-Mediated Protection of Dopaminergic Neurons in a Chronic MPTP-Minipump Mouse Model of Parkinson Disease (2011) (59)
Genotype in the 24-kDa subunit gene (NDUFV2) of mitochondrial complex I and susceptibility to Parkinson disease. (1998) (59)
Effects of UCH‐L1 on α‐synuclein over‐expression mouse model of Parkinson’s disease (2009) (59)
An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. (1994) (59)
Inflammation and infection in Parkinson's disease. (2006) (59)
Parkin and Endoplasmic Reticulum Stress (2003) (58)
Decline of striatal dopamine release in parkin‐deficient mice shown by ex vivo autoradiography (2006) (57)
I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway. (2015) (57)
Adult type neuronal storage disease with neuraminidase deficiency (1979) (57)
Common anti-apoptotic roles of parkin and α-synuclein in human dopaminergic cells (2005) (57)
Accumulation of 4-hydroxynonenal-modified proteins in hippocampal CA1 pyramidal neurons precedes delayed neuronal damage in the gerbil brain (2000) (56)
Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group. (2003) (56)
Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease (2007) (55)
Posterior hypoperfusion in parkinson's disease With and without dementia measured with arterial spin labeling MRI (2011) (54)
New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism (2003) (54)
Postischemic accumulation of lipid peroxidation products in the rat brain: immunohistochemical detection of 4-hydroxy-2-nonenal modified proteins (1997) (52)
Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains (2001) (52)
Accumulation of α-Synuclein Triggered by Presynaptic Dysfunction (2012) (51)
Up-regulation of hMUTYH, a DNA repair enzyme, in the mitochondria of substantia nigra in Parkinson’s disease (2006) (50)
Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4-tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain (1992) (50)
PARKIN as a pathogenic gene for autosomal recessive juvenile parkinsonism. (2000) (50)
Autosomal-recessive juvenile parkinsonism in a Jewish Yemenite kindred: mutation of Parkin gene. (1999) (49)
Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study. (2014) (48)
Clinical, pathologic and genetic studies on autosomal recessive early-onset parkinsonism with diurnal fluctuation. (1998) (48)
A microdeletion of D6S305 in a family of autosomal recessive juvenile parkinsonism (PARK2). (1998) (48)
Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. (2006) (48)
Familial Parkinsonism with digenic parkin and PINK1 mutations (2008) (48)
Point mutations in mitochondrial tRNA genes: sequence analysis of chronic progressive external ophthalmoplegia (CPEO) (1994) (47)
Mitochondrial dysfunction in Parkinson's disease. (2002) (47)
Recurrent cranial neuropathy as a clinical presentation of idiopathic inflammation of the dura mater: a possible relationship to Tolosa-Hunt syndrome and cranial pachymeningitis (1998) (47)
Recessive Parkinson's disease (2006) (46)
Clinical and genetic studies of families with the tau N279K mutation (FTDP-17) (2002) (46)
Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity and ATP synthesis by tetrahydroisoquinoline (1988) (45)
Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration. (2002) (45)
Effects of various tetrahydroisoquinoline derivatives on mitochondrial respiration and the electron transfer complexes (1998) (44)
Neuronal specificity of alpha-synuclein toxicity and effect of Parkin co-expression in primates. (2007) (44)
Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study (2010) (42)
Lewy body pathology in a patient with a homozygous Parkin deletion (2013) (42)
Haploinsufficiency at the α‐synuclein gene underlies phenotypic severity in familial Parkinson’s disease (2003) (41)
Recombinant human granulocyte colony‐stimulating factor protects against MPTP‐induced dopaminergic cell death in mice by altering Bcl‐2/Bax expression levels (2006) (41)
Camptocormia, axial dystonia, and parkinsonism: Phenotypic heterogeneity of a parkin mutation (2003) (41)
Changes in γ-aminobutyrate, glutamate, aspartate, glycine, and taurine contents in the striatum after unilateral nigrostriatal lesions in rats (1986) (40)
Cortical ballooned neurons in progressive supranuclear palsy (1996) (40)
Significance of CSF total neopterin and biopterin in inflammatory neurological diseases (1992) (40)
Mechanism and treatment of dropped head syndrome associated with parkinsonism. (2009) (40)
Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study (2007) (40)
Induction of Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) Expression in Rat Brain after Focal Ischemia/Reperfusion (2002) (40)
Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells. (2005) (40)
Placebo‐controlled, double‐blind dose‐finding study of entacapone in fluctuating parkinsonian patients (2007) (39)
Familial cortical tremor with epilepsy: an under-recognized familial tremor (1998) (39)
Progress in the clinical and molecular genetics of familial parkinsonism (2000) (39)
Parkin gene causing benign autosomal recessive juvenile parkinsonism (2001) (38)
An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease (1997) (38)
Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain. (2003) (38)
Early onset parkinsonism with diurnal fluctuation maps to a locus for juvenile parkinsonism (1998) (38)
The frequency of cardiac valvular regurgitation in Parkinson's disease (2008) (37)
Autosomal recessive juvenile parkinsonism: A key to understanding nigral degeneration in sporadic Parkinson's disease (2000) (37)
Establishment of modified chimeric mice using GFP bone marrow as a model for neurological disorders (2003) (35)
Official Japanese Version of the International Parkinson and Movement Disorder Society–Unified Parkinson's Disease Rating Scale: Validation Against the Original English Version (2014) (35)
123I-MIBG myocardial scintigraphy for the diagnosis of DLB: a multicentre 3-year follow-up study (2018) (34)
Association between the gene encoding the E2 subunit of the α‐ketoglutarate dehydrogenase complex and Parkinson's disease (1998) (34)
Dual Role of Fc&ggr; Receptor in Transient Focal Cerebral Ischemia in Mice (2004) (34)
Genetic association between susceptibility to Parkinson's disease and α 1-antichymotrypsin polymorphism (1997) (34)
Sweet's syndrome associated with encephalitis (2001) (33)
Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease (2010) (33)
Programmed cell death‐2 isoform1 is ubiquitinated by parkin and increased in the substantia nigra of patients with autosomal recessive Parkinson's disease (2009) (33)
An extremely unusual presentation of varicella zoster viral infection of cranial nerves mimicking Garcin syndrome (2006) (32)
Music therapy in parkinson's disease: Improvement of parkinsonian gait and depression with rhythmic auditory stimulation (2006) (32)
Sensory neuropathy in autosomal recessive juvenile parkinsonism (PARK2). (2003) (32)
Transdermal rotigotine in advanced Parkinson’s disease: a randomized, double-blind, placebo-controlled trial (2014) (31)
Colocalization of Bcl-2 and 4-hydroxynonenal modified proteins in microglial cells and neurons of rat brain following transient focal ischemia (1998) (30)
Bell's palsy-induced blepharospasm (2002) (30)
Genetic association analyses of PHOX2B and ASCL1 in neuropsychiatric disorders: evidence for association of ASCL1 with Parkinson’s disease (2005) (30)
Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier (2007) (30)
Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa–Undertreated Parkinson Disease: A Double-Blind, Randomized Trial (2012) (30)
Twenty years since the discovery of the parkin gene (2017) (30)
Synthetic peptide corresponding to 30 amino acids of the C-terminal of neuron-specific enolase promotes survival of neocortical neurons in culture. (1994) (29)
Progress in familial Parkinson's disease. (2006) (28)
Mutation analyses in amyotrophic lateral sclerosis/parkinsonism–dementia complex of the Kii peninsula, Japan (2008) (28)
An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys (1996) (27)
Dominant‐negative effect of mutant valosin‐containing protein in aggresome formation (2006) (27)
Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra (2006) (27)
Familial hemifacial spasm: report of cases and review of literature (2002) (27)
[Progress in Parkinson's disease]. (2004) (26)
Myoclonic tremulous movements in multiple system atrophy are a form of cortical myoclonus (2005) (26)
Neurotoxic effects of papaverine, tetrahydropapaverine and dimethoxyphenylethylamine on dopaminergic neurons in ventral mesencephalic-striatal co-culture (1997) (25)
Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease (2014) (25)
Transdermal rotigotine in early stage Parkinson's disease: A randomized, double‐blind, placebo‐controlled trial (2013) (25)
Structural organization and chromosomal localization of the human nuclear gene (NDUFV2) for the 24-kDa iron-sulfur subunit of complex I in mitochondrial respiratory chain. (1995) (25)
Superoxide dismutase activity in early stages of development in normal and dystrophic chickens. (1984) (25)
Patient‐reported convenience of once‐daily versus three‐times‐daily dosing during long‐term studies of pramipexole in early and advanced Parkinson’s disease (2013) (24)
Familial Parkinson’s disease: a hint to elucidate the mechanisms of nigral degeneration (2003) (24)
Statistical parametric mapping of immunopositive cell density (2006) (24)
Alpha-synuclein overexpression model. (2006) (24)
Dual role of Fcgamma receptor in transient focal cerebral ischemia in mice. (2004) (24)
The parkin gene S/N167 polymorphism in Australian Parkinson's disease patients and controls. (2001) (24)
Potential of Neuroprotective Therapy in Parkinson’s Disease (1994) (24)
Apolipoprotein E receptor 2 is involved in neuritic plaque formation in APP sw mice (2004) (24)
Importance of familial Parkinson's disease and parkinsonism to the understanding of nigral degeneration in sporadic Parkinson's disease. (2000) (23)
Dimethoxyphenylethylamine and tetrahydropapaverine are toxic to the nigrostriatal system (1997) (23)
Recent Research Progress in and Future Perspective on Treatment of Parkinson's Disease (2014) (23)
Excitatory amino acid transporter 2 associates with phosphorylated tau and is localized in neurofibrillary tangles of tauopathic brains (2009) (22)
Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs (2017) (22)
Golden mean to longevity: Rareness of mitochondrial cytochrome b variants in centenarians but not in patients with Parkinson's disease (2002) (22)
Inhibition of mitochondrial respiration by 1,2,3,4-tetrahydroisoquinoline-like endogenous alkaloids in mouse brain (1990) (22)
Adeno-associated virus-mediated antiapoptotic gene delivery: in vivo gene therapy for neurological disorders. (2002) (22)
Contrasting genotypes of the tau gene in two phenotypically distinct patients with P301L mutation of frontotemporal dementia and parkinsonism linked to chromosome 17 (2002) (21)
Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study (1985) (21)
Evaluation of the somatosensory evoked blink response in patients with neurological disorders. (1996) (21)
Dopaminergic Neurotoxins, MPTP and MPP+, Inhibit Activity of Mitochondrial NADH-Ubiquinone Oxidoreductase (1986) (21)
LRRK2 P755L variant in sporadic Parkinson's disease (2008) (21)
Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease (2014) (21)
Genetics of Parkinson's disease. (1999) (20)
Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease. (2003) (20)
Apoptosis in neurodegenerative disorders. (1997) (20)
Hoarseness due to bilateral vocal cord paralysis as an initial manifestation of familial amyotrophic lateral sclerosis (2005) (20)
Ectopic expression of α‐synuclein affects the migration of neural stem cells in mouse subventricular zone (2010) (20)
Genetic and environmental factors in the pathogenesis of Parkinson's disease. (1999) (19)
Relationship between Parkinson disease with dementia and dementia with Lewy bodies. (2005) (19)
An analysis of the ultrastructural findings in infantile neuroaxonal dystrophy (Seitelberger's disease) (1974) (19)
Serum creatine kinase is elevated in patients with Parkinson's disease: a case controlled study. (2003) (19)
A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease (2017) (19)
α-Synuclein overexpression model (2006) (19)
Alteration in the differentiation-related molecular expression in the subventricular zone in a mouse model of Parkinson's disease (2008) (19)
Differential regional distribution of phosphorylated tau and synapse loss in the nucleus accumbens in tauopathy model mice (2011) (18)
Pseudo-autosomal dominant inheritance of PARK2: two families with parkin gene mutations (2003) (18)
An apparently sporadic case with parkin gene mutation in a Korean woman. (2001) (18)
Genotype–phenotype correlation: Familial Parkinson disease (2003) (18)
[Validation of the Japanese version of the Parkinson's Disease Questionnaire]. (2003) (17)
Developmental changes in the expression of parkin and UbcR7, a parkin‐interacting and ubiquitin‐conjugating enzyme, in rat brain (2001) (17)
Glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase and glyceraldehyde-3-phosphate dehydrogenase activities in early stages of development in dystrophic chickens (1985) (17)
Mitochondrial energy crisis in Parkinson's disease. (1993) (17)
Genetic vitamin E deficiency does not affect MPTP susceptibility in the mouse brain (2006) (16)
Familial Parkinsonism with Apathy, Depression and Central Hypoventilation (Perry’s Syndrome) (2002) (16)
Neurosarcoidosis Associated with Interferon Therapy (2001) (16)
The L-DOPA story - an early Japanese contribution (2000) (15)
Identification of neurite outgrowth active sites on the laminin alpha4 chain G domain. (2005) (15)
EIF4G1 gene mutations are not a common cause of Parkinson's disease in the Japanese population. (2014) (15)
Parkin gene therapy for α-synucleinopathy: A rat model of Parkinson's disease (2006) (15)
Characterization of multimetric variants of ubiquitin carboxyl-terminal hydrolase L1 in water by small-angle neutron scattering. (2006) (15)
Analysis of eighteen deletion breakpoints in the parkin gene. (2009) (15)
An Autopsy Case of Schilder’s Variant of Multiple Sclerosis (Schilder’s Disease) (2006) (14)
Tau accumulation in a patient with pallidonigroluysian atrophy (2001) (14)
[Excessive daytime sleepiness and low CSF orexin-A/hypocretin-I levels in a patient with probable progressive supranuclear palsy]. (2003) (14)
Inhibition of ATP synthesis by 1-methyl-4-phenylpyridinium ion (MPP+) in mouse brain in vitro and in vivo. (1990) (13)
Capgras syndrome in Parkinson's disease (2001) (13)
Clinical and genetic studies on familial parkinsonism: The first report on a parkin gene mutation in a Taiwanese family (2001) (13)
Mutation analysis for DJ-1 in sporadic and familial parkinsonism: Screening strategy in parkinsonism (2009) (13)
A new mutation in the GCH1 gene presents as early-onset Parkinsonism. (2009) (13)
Phosphorylated IκBα is a component of Lewy body of Parkinson’s disease (2005) (12)
Dopamine deficiency may lead to capgras syndrome in Parkinson's disease with dementia. (2010) (12)
Rapid screening of ATP13A2 variant with high‐resolution melting analysis (2010) (12)
Effect of long-term administration of 1,2,3,4-tetrahydroisoquinoline (TIQ) on striatal dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) content in mice (1988) (12)
Early Addition of Selegiline to L-Dopa Treatment is Beneficial for Patients With Parkinson Disease (2010) (12)
Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease (2011) (12)
The isolation of neural stem cells from the olfactory bulb of Parkinson's disease model (2007) (12)
Blepharospasm associated with multiple system atrophy: a case report and review of the literature. (2004) (12)
Success rate, efficacy, and safety/tolerability of overnight switching from immediate‐ to extended‐release pramipexole in advanced Parkinson's disease (2013) (12)
A multi‐center, double‐blind study on slow‐release bromocriptine in the treatment of Parkinson's disease (1991) (12)
Nuclear localization of the 20S proteasome subunit in Parkinson's disease (2006) (12)
Effects of blockade of metabotropic glutamate receptors in the subthalamic nucleus on haloperidol-induced Parkinsonism in rats (2000) (12)
Positional cloning of the autosomal recessive juvenile parkinsonism (AR-JP) gene and its diversity in deletion mutations. (1999) (11)
Practical Guidelines for the Drug Treatment of Parkinson’s Disease (1994) (11)
Talipexole protects dopaminergic neurons from methamphetamine toxicity in C57BL/6N mouse (1998) (11)
Genetic aspects of Parkinson's disease. (1999) (11)
Geographic and ethnic differences in frequencies of two polymorphisms (D/N394 and L/I272) of the parkin gene in sporadic Parkinson's disease. (2005) (11)
Loss of DARPP-32 and calbindin in multiple system atrophy (2013) (11)
Refinement of the gene locus for autosomal recessive juvenile parkinsonism (AR-JP) on chromosome 6q25.2-27 and identification of markers exhibiting linkage disequilibrium (1998) (11)
A case of frontotemporal dementia with tau P301L mutation in the Far East (2000) (11)
[Amyotrophic lateral sclerosis presented with alexia of kanji and word meaning aphasia]. (2002) (11)
[A case of brainstem vascular malformation with isolated trochlear nerve palsy as the initial symptom]. (1991) (10)
Isolated reversible splenial lesion in adult meningitis: a case report and review of the literature. (2007) (10)
Absence of linkage to 8q24 in a European family with familial adult myoclonic epilepsy (FAME). (2002) (10)
I 2020 T mutant LRRK 2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT / GSK-3 β signaling pathway (2015) (10)
Drug therapy of Parkinson's disease. An overview. (1992) (10)
Effects of the globus pallidus lesion on the induction of c-Fos by dopaminergic drugs in the striatum possibly via pallidostriatal feedback loops (1998) (10)
Structural Dimorphism in the Mitochondrial Targeting Sequence in the Human Manganese Superoxide Dismutase Gene: A Predictive Evidence for Conformational Change to Influence Mitochondrial Transport and a Study of Allelic Association in Parkinson's Disease: Volume226,Number 2 (1996), pages 561–565: (1996) (10)
Mixed multiple system atrophy and progressive supranuclear palsy: a clinical and pathological report of one case (2014) (10)
Glial localization of four‐repeat tau in atypical progressive supranuclear palsy (2004) (10)
Postural effects of unilateral blockade of glutamatergic neurotransmission in the subthalamic nucleus on haloperidol-induced akinesia in rats (1998) (10)
[Chronic inflammatory demyelinating polyneuropathy followed by systemic lupus erythematosus and Sjögren syndrome: a case report]. (2006) (10)
Anticoagulant Therapy with a Selective Thrombin Inhibitor for Acute Cerebral Infarction: Usefulness of Coagulation Markers for Evaluation of Efficacy (2002) (10)
Analyzer workshop on the treatment of Parkinson's disease. (1997) (9)
Dystonic posturing and circling behaviors induced by dopaminergic agents in rats with unilateral globus pallidus lesions (1998) (9)
A clue to the pathogenesis of dopa‐responsive dystonia (1995) (9)
Gene therapy for Parkinson's disease. (2013) (9)
Juvenile parkinsonism: ventricular CSF biopterin levels and clinical features (1992) (9)
Mutation Analysis of the PINK 1 Gene in 391 Patients With Parkinson Disease (2008) (9)
Propriospinal Negative Myoclonus (2001) (8)
Phosphorylated IkappaBalpha is a component of Lewy body of Parkinson's disease. (2005) (8)
Neurophysiological analysis of ataxia in capsular ataxic hemiparesis (1987) (8)
Effects of donepezil dose escalation in Parkinson's patients with dementia receiving long‐term donepezil treatment: an exploratory study (2014) (8)
Molecular mechanisms of nigral neurodegeneration in Park2 and regulation of parkin protein by other proteins. (2006) (8)
Clustering of Risk Factors Increases the Incidence of Echolucent Carotid Plaque in Stroke Patients (2006) (8)
Where do we stand in the treatment of Parkinson's disease? (2007) (7)
Role of mitrochondria in the etiology and pathogenesis of Parkinson's disease (1995) (7)
No evidence for pathogenic role of GIGYF2 mutation in Parkinson disease in Japanese patients (2010) (7)
Blind source separation and chaotic analysis of EEG for judgment of brain death (2001) (7)
Specific detection of deleted mitochondrial DNA by in situ hybridization using a chimera probe. (1996) (7)
Adeno-associated viral vector-mediated gene transduction in mesencephalic slice culture (2011) (7)
[A long-term clinical effect of selegiline hydrochloride on Parkinson's disease]. (1996) (6)
A large Japanese family with Machado–Joseph disease: clinical and genetic analysis (1999) (6)
Autosomal Recessive Juvenile Parkinsonism (AR-JP): Genetic Diagnosis. (2001) (6)
Pathological and biochemical studies on a case of Pick disease with severe white matter atrophy (2006) (6)
Four-repeat tau-positive Pick body-like inclusions are distinct from classic Pick bodies (2005) (6)
What Does Apoptosis Have To Do With Parkinson ’ s Disease ? (6)
Effects of test H-reflex size on reciprocal inhibition in forearm muscles (1999) (5)
More than 20 years of the discovery of Park2 (2020) (5)
Bilateral Hypoglossal Nerve Involvement in Chronic Inflammatory Demyelinating Polyneuropathy (2004) (5)
Globus pallidus lesions inhibit the induction of c-Fos by haloperidol in the basal ganglia output nuclei in rats (1998) (5)
Parkin and Parkinson disease. (2012) (5)
L-threo-3, 4-dihydroxyphenylserine Treatment for Dementia of Various Etiologies (1986) (5)
Eyelid motor extinction (2001) (5)
[Diagnostic criteria for brain death]. (1993) (5)
[Molecular pathogenesis of familial Parkinson's disease]. (2000) (5)
Myoclonic tremor in patients with parkinsonian‐type multiple system atrophy (2001) (5)
Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation (2005) (4)
Studies on the pathogenesis of Parkinson's disease in Japan. (1994) (4)
A Histochemical Study of Iron and Ferritin in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Induced Hemiparkinsonian Monkeys (1996) (4)
Cortical myoclonus due to hypocalcemia 12 years after thyroidectomy (2006) (4)
[Progress in the basic and clinical aspects of Parkinson's disease]. (2004) (4)
Mitochondrial abnormalities in Parkinson's disease (1992) (4)
Clinical manifestations and etiology in stroke patients with cancer: usefulness of coagulation and fibrinolytic markers (2006) (4)
The unrelated communication interlude (UCI)--an automatic behavior phenomenon in Parkinson's disease. (2012) (4)
No evidence for pathogenic role of GIGYF2 mutation in Parkinson disease in Japanese patients. (2010) (3)
Mitochondrial energy crisis as a mechanism for nigral cell death (1991) (3)
Long-Term Selegiline Monotherapy for the Treatment of Early Parkinson Disease (2019) (3)
Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. (1993) (3)
Ubiquitination of a Novel form of α-Synuclein by Parkin (2002) (3)
[A case of neuralgic amyotrophy in the lower extremity (lumbosacral radiculoplexus neuropathy)]. (2007) (3)
Cortical Reflex Action Myoclonus in Neurosyphilis (2001) (3)
[Phase 2 clinical study of 123I-IBF, a dopamine D2 receptor imaging agent, to evaluate clinical efficacy and safety in Parkinson's disease and Parkinson syndromes]. (1999) (3)
Second International Symposium on the Treatment of Parkinson's Disease (1998) (3)
Impaired glucose tolerance and insulin resistance in patients with stroke (2006) (3)
[An 81-year-old man with personality change, dementia, and gait disturbance with diffuse leukoaraiosis of the cerebral white matter]. (2006) (3)
INCREASED DENSITY OF MITOCHONDRIA ISOLATED FROM THE SKELETAL MUSCLE OF A PATIENT WITH MITOCHONDRIAL MYOPATHY (1988) (3)
[Japanese contribution to the understanding of frontotemporal dementia and parkinsonism linked to chromosome 17(FTDP-17)]. (2003) (3)
[31P magnetic resonance spectroscopy(MRS) study in basal ganglia of patients with Parkinson's disease]. (1997) (3)
[Parkin gene and its function; a key to understand nigral degeneration]. (1999) (2)
[Concept and diagnostic criteria of Parkinson's disease and parkinsonism]. (1997) (2)
[The role of oxygen free radicals in the aging of the brain]. (1990) (2)
Isolated Deep Cerebral Venous Thrombosis: An Important Cause for Isolated Mental Impairment (2004) (2)
Contents Vol. 45, 2001 (2001) (2)
Pathophysiology of Parkinson’s Disease, Neurochemical Pathology: Other Neurotransmitters (2004) (2)
Tetrahydrobiopterin Therapy for Juvenile Parkinsonism (1990) (2)
5th International Symposium on the Treatment of Parkinson's Disease (2001) (2)
Dopamine cell death by a single genetic mechanism: phenotypic analysis and linkage study of autosomal recessive juvenile parkinsonism. (1999) (2)
Interaction between parkin and alpha‐synuclein (2008) (2)
Seventeenth Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders (2003) (2)
P2.159 Efflcacy and safety of once-daily (qd) pramipexole extended-release for advanced Parkinson's disease (2009) (2)
Parkin binds the Rpn10 subunit of 26S proteasomes with the ubiquitin-like domain (2003) (2)
Pseudoathetosis caused by migrated cervical disc. (2007) (2)
Mortality Associated with Selegiline in Parkinson’s Disease (1997) (2)
Piroheptine prevents loss of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced striatal loss of dopamine in mice. (1986) (2)
[Studies on pathogenesis of muscular dystrophy: levels of thiobarbituric acid-reactive products in avian muscular dystrophy]. (1984) (2)
[A patient with Hashimoto's encephalopathy showing subacute global cognitive dysfunction]. (2003) (1)
Neuroimaging, Parkinson’s Disease (2010) (1)
Dizziness and Vertigo (1992) (1)
The Effect of Tetrahydroisoquinoline on the Mitochondrial Respiration (1990) (1)
Pathogenesis of Parkinson’s disease: iron and mitochondrial DNA deletion (1993) (1)
Evaluation of cerebral infarction using B-mode ultrasonic and doppler flowmeter. (1992) (1)
Treatment of Parkinson's Disease after the Wearing Off Sets in (2019) (1)
Familial Parkinson^|^apos;s disease based on the single gene defects (2001) (1)
[A case of brachial plexus neuropathy who presented with acute paralysis of the hand after sleep]. (2002) (1)
Colocalization of Parkin with α-Synuclein in the Lewy Bodies of Parkinson Disease (2002) (1)
[Clinical characteristics and linkage analysis of autosomal recessive form of juvenile parkinsonism(AR-JP)]. (1997) (1)
[Posterior leukoencephalopathy syndrome presenting with bilateral ataxie optique: a case report]. (2005) (1)
Total Biopterin and Neopterin Levels in the Ventricular CSF Patients with Parkinson’s Disease (1990) (1)
[A 59-year-old woman with personality change and abnormal behavior followed by amyotrophy and dementia]. (2005) (1)
Corrigendum to “Common anti-apoptotic roles of parkin and α-synuclein in human dopaminergic cells” [Biochem. Biophys. Res. Commun. 332 (2005) 233–240] (2005) (1)
Definition and Classification of Parkinsonian Drugs (2019) (1)
Sustained efficacy and tolerability of pramipexole extended-release as adjunctive treatment in advanced Parkinson's disease (2010) (1)
[Autosomal recessive juvenile parkinsonism: its pathogenesis is involved in the ubiquitin-proteasome pathway]. (2000) (1)
P2.155 Simple overnight switching from immediate- to extended-release pramipexole in early Parkinson's disease at the same daily dosage (2009) (1)
Generalized Convulsions After Consuming a Large Amount of Gingko Nuts (2001) (1)
[Familial amyotrophic lateral sclerosis with rapid progression]. (2005) (1)
Parkin as ubiquitin ligase (2001) (1)
An update on the management of juvenile and young-onset Parkinson’s disease (2012) (1)
Pathogenesis of Nigral Cell Death in Parkinson’s Disease (1995) (1)
1091 Possibility for neurogenesis in substantia nigra of Parkinsonian brain (2005) (1)
Movement Disorders in Neurologic and Systemic Disease: Movement disorders in neoplastic brain disease (2014) (1)
Parkin Mutations (Park 2) (2003) (1)
Neurology and clinical neuroscience - a textbook of neurology (2007) (1)
2.265 LONG-TERM SAFETY AND SUSTAINED EFFICACY OF EXTENDED-RELEASE PRAMIPEXOLE IN EARLY AND ADVANCED PARKINSON'S DISEASE (2012) (0)
Distribution of gamma amino butyric acid glutamate and aspartate in the thalamus of patients with basal ganglia disorders (1982) (0)
Autosomal Recessive Juvenile Parkinsonism and the Ubiquitin Pathway (2002) (0)
Comparisons among responses to pramipexole extended-release as adjunctive treatment in Japanese and non-Japanese studies of advanced Parkinson's disease (2010) (0)
[Parkinson's disease]. (1994) (0)
Author/Subject Indexes (1993) (0)
Contents Vol. 22, 2006 (2006) (0)
Small-angle neutron scattering (SANS) and dynamic light scattering (DLS) analyses of the initial aggregation process of tau by oxidative stress (2007) (0)
[The Parkin gene and its product in AR-JP]. (1999) (0)
Sustained off-time decrease in patients using pramipexole extended-release as adjunctive treatment in advanced Parkinson's disease (2010) (0)
P2.153 Once-daily pramipexole extended-release (ER) demonstrated non-inferiority compared to immediate release (IR) tid dosing in early Parkinson's disease (2009) (0)
P4-157 Accumulation of phosphorylated alpha-synuclein and tau in Alzheimer’s disease and dementia with Lewy bodies (2006) (0)
[Japanese clinical statistical data of patients with parkinson's disease]. (1992) (0)
Solution structure of ubiquitin-like domain of human parkin (2003) (0)
[A study on long-term levodopa therapy in Parkinson's disease]. (1982) (0)
Comparison between the efficacy of prostacyclin analogue (beraprost) with low-dose aspirin and aspirin alone to platelet aggregation and serum prostanoids (thromboxane B2 and 6-ketoPGF1.ALPHA.). (1995) (0)
[Progress in studies of Parkinson's disease]. (2000) (0)
Determination of platelet function in patients with cerebral infarction on antiplatelet therapy (1993) (0)
Electrophysiological and other auxiliary investigations in patients with Parkinson’s disease dementia (2010) (0)
[Discovery of the parkin gene; the gene for young onset autosomal recessive parkinsonism (AR)]. (2007) (0)
Etiology, Pathogenesis, and Genetics of Parkinson’s Disease (2002) (0)
Neurophysiology of blepharospasm in multiple system atrophy (2005) (0)
244. New Gene Therapy for Parkinson's Disease by Down Regulation of α-Synuclein (2006) (0)
Chapter 13 – Neuroprotection in Parkinson's Disease (2005) (0)
Meeting details (2005) (0)
[Mitochondrial dysfunction in Parkinson's disease]. (2002) (0)
The hallmark of Parkinson’s disease (PD) is a specific degeneration of dopaminergic neurons in the substantia nigra (SN). The cause of nigral dopaminergic neuronal cell death in PD and its underlying mechanisms (2017) (0)
[Studies on Lewy bodies on their 100th year: a discussion]. (2012) (0)
2.263 PATIENT-REPORTED CONVENIENCE OF ONCE-DAILY VS TID DOSING DURING LONG-TERM STUDIES OF PRAMIPEXOLE IN EARLY AND ADVANCED PARKINSON'S DISEASE (2012) (0)
Somatosensory evoked potentials in striatonigral degeneration and olivopontocerebellar atrophy (2005) (0)
[A 76-year-old woman with personality change, dementia and parkinsonism]. (2005) (0)
Advances in parkin gene therapy—A primate study (2007) (0)
Proteine parkine utilisee comme ubiquitine ligase (2001) (0)
P2.089 Efflcacy of pramipexole extended release (ER) and switching from pramipexole immediate release (IR) to ER in Japanese advanced PD patients (2009) (0)
In memoriam, Professor Hirotaro Narabayashi (September 4, 1922–March 18, 2001) (2002) (0)
Investigation of Carotid Stenosis and Blood Flow in Patients with Middle Cerebral Artery Thrombosis and Embolism by Duplex Ultrasonography (1993) (0)
Up to what extent has the etiology of Parkinson^|^apos;s disease been elucidated? (1995) (0)
The parkin protein-as a ubiquitin ligase (2001) (0)
Subject Index Vol. 32, 1992 (1992) (0)
[Late onset hemiparkinsonism-hemiatrophy syndrome: a case report]. (2005) (0)
949. AAV-Parkin Gene Therapy for Alpha-Synucleinopathy as Parkinson's Diseased Model (2005) (0)
Chapter 2 Neurogenetics in Parkinson ’ s Disease (0)
[Etiology and pathogenesis of parkinson's disease]. (1996) (0)
Effect of Lymphocytapheresis on Steroid-Resistant Patients with Polymyositis(Neurological Disease,General Presentation) (1996) (0)
S.27.04 Genetic aetiopathogenesis of Parkinson's disease (2004) (0)
Subject Index Vol 38, Suppl. 1, 1997 (1997) (0)
PS-5-4 The somatosensory evoked blink response: observation in neurological disorders (1995) (0)
Inhibitory Effects of Endogenous Tetrahydroisoquinolines on Mitochondrial Respiration in Mouse Brain (1995) (0)
P4-334 Chronic oral lithium administration attenuates motor disturbance through reducing tau phosphorylation in a tauopathy model mice (2006) (0)
Review Inflammation and infection in Parkinson's disease (2006) (0)
Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease (vol 4, pg 195, 2002) (2002) (0)
[Parkinson's disease; etiology and animal model]. (1991) (0)
[Malignant migraine]. (2002) (0)
Subject Index Vol. 45, 2001 (2001) (0)
The cause of Parkinson disease is followed. (2005) (0)
Parkinson's disease.Advance in diagnosis and treatments.2.Advance in pathosis and diagnosis.2.3 main syndromes in Parkinson's disease and the pathophysiology. (1994) (0)
Evaluation ofthesomatosensory evokedblink responseinpatients withneurological disorders (1996) (0)
Treatment of Parkinson's Disease: 1st Sandoz Symposium, Tokyo, October 1992 (1993) (0)
Editorial Board (2007) (0)
1328 Neurotoxicities of MPP+ and tiq derivatives on dopaminergic neurons in ventral mesencephalic striatal co-culture (1993) (0)
Apoptosis in MPP+-Treated Mesencephalic-Striatal Co-Culture and MPTP-Induced Hemiparkinsonian Monkeys (1996) (0)
[Juvenile parkinsonism]. (2003) (0)
[Progress in diagnosis and therapy for Parkinson's disease]. (2002) (0)
A pharmacological analysis of circling behavior by chemical stimulation of pedunculopontine nucleus (1985) (0)
Neurogenetics in Parkinson's Disease (2008) (0)
Ubiquitin-Proteasome Pathway is a Key to Understanding of Nigral Degeneration in Autosomal Recessive Juvenile Parkinson’s Disease (2002) (0)
[In pursuit of the causes for Parkinson disease]. (2005) (0)
Dns or genes, which are involved in Parkinson's disease (1999) (0)
Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue (2012) (0)
Mitochondrial abnormalities in Parkinson^|^apos;s disease and MPTP-induced Parkinsonism (1990) (0)
Mutant ubiquitin accumulate in CA1 pyramidal cells after transient global ischemia in gerbil (2005) (0)
Molecular Biology of α-Synuclein (2002) (0)
Iodobenzylguanidine Myocardial Scintigraphy in Dementia with Lewy Bodies (2015) (0)
P3.132 Alpha-synuclein in stem cells (2009) (0)
Erythropoietin regulated by hypoxia-inducible factor-1 and recombinant human erythropoietin protect cultured neurons from hypoxic and reoxygenic injury (2005) (0)
Neuroprotective role of Fc gamma receptor in ischemia-reperfusion injury using Fc gamma receptor knockout mice (2005) (0)
Correction (2004) (0)
16th Symposium on the Treatment of Parkinson's Disease, September 15, 2007, Tokyo, Japan. Preface. (2008) (0)
[A long-term clinical effect of selegiline hydrochloride on Parkinson's disease]. (1994) (0)
1556 Differential expression of c-Fos immunoreactivity in the inferior olive under the harmaline-induced tremor in rats (1997) (0)
[A 61-year-old man with rapidly progressing dementia and gait disturbance]. (1993) (0)
3.205 NECDIN PREVENTS LOSS OF DOPAMINERGIC NEURONS IN ANIMAL MODELS OF PARKINSON'S DISEASE (2012) (0)
Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease [Parkinsonism Relat Disord 6 (4) (2000) 195–197] (2002) (0)
Chairman's remark (2003) (0)
Quantitative Evaluation of Vocal Changes in Parkinson’s Disease: Intercorrelation among Voice Parameters and Monoamine Systems (1990) (0)
[Long-term treatment of Parkinson's disease patients with selegiline hydrochloride (FPF 1100): outcome of 5-year treatment]. (2002) (0)
A case of transcortical motor aphasia caused by a frontal subcortical lesion (1992) (0)
Subject Index Vol. 22, 2006 (2006) (0)
A COMPREHENSIVE STUDY ON THE MECHANISM UNDERLYING THE PATHOGENESIS OF PARKINSON'S DISEASE AND ITS TREATMENT (1998) (0)
60-year-old female with SLE complicated by progressive ataxia (1991) (0)
[The 3 major symptoms and their physiopathology in Parkinson disease]. (1994) (0)
1st Sandoz Symposium on the Treatment of Parkinson’s Disease, Vol. 33(suppl 1), 1993 (1993) (0)
Parkinsonian Drugs: Guidelines for Japan (2020) (0)
Etiology and pathogenesis of Parkinson^|^apos;s disease (2006) (0)
[Effects and side effects of levodopa in parkinsonism - results of a collaborative study. (3) Side effects of levodopa]. (1976) (0)
59-year-old male with Parkinsonism died with malignant syndrome-like terminal (1991) (0)
[Studies on pathogenesis of Parkinson's disease]. (2005) (0)
[A patient with focal bi-parietal atrophy presenting motor clumsiness and cortical sensory loss]. (1998) (0)
[Gene abnormalities in Parkinson disease]. (2005) (0)
Complex I Deficiency in Parkinson’s Disease and MPTP-Induced Experimental Parkinsonism (1990) (0)
Subject Index Vol. 38, Suppl. 2, 1997 (1997) (0)
Parkin and Synuclein in Parkinson's Disease (2003) (0)
2K1545 Parkin binds the Rpn10 subunit of 26S proteasomes with the ubiquitin-like domain (2002) (0)
Discussion: 8—11 A.M. - February 9, 1993 (1994) (0)
[Effects of the "drug holiday" on problems of long-term levodopa therapy against Parkinson's disease]. (1984) (0)
I2020T LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3beta signaling pathway (2016) (0)
Parkinson Symptoms in Dementia with Lewy Bodies (2017) (0)
a Chromosome 6q-Linked Parkinsonism (1998) (0)
Anti-Apoptotic Therapy for Parkinson’s Disease: Overexpression of an APAF-1-Dominant-Negative Inhibitor Can Block MPTP Toxicity (2002) (0)
Accumulation of 4-hydroxy-2-nonenal-modified proteins in the white matter damage in chronic cerebral hypo-perfusion rat mode (2005) (0)
Progress in and Future Perspective on Treatment of Parkinson ’ s Disease (2014) (0)
242. Neuronal Specificity of α-Synuclein Toxicity and the Effect of Parkin Co-Expression in Primates (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Yoshikuni Mizuno?

Yoshikuni Mizuno is affiliated with the following schools: